Junna Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junna Ye has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
Zhuochao Zhou
Department of Rheumatology and Immunology Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
20 shared publications- Chengde Yang
Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
18 shared publications Xiaobing Cheng
Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai
18 shared publicationsYue Sun
Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai
18 shared publicationsHonglei Liu
Department of Rheumatology and Immunology Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China
16 shared publicationsJialin Teng
Department of Rheumatology and Immunology Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
16 shared publications
Latest Publications
- Open Access
Comprehensive Immune Repertoires of T Cell Receptor and B Cell Receptor Identify Key Immune Features Associated With Disease Activity of Systemic Lupus Erythematosus
We integrated immune repertoire sequencing (CD4+ and CD8+ T cell receptor [TCR], B cell receptor [BCR]) and transcriptional profiling to characterize the peripheral immune landscape in 32 active systemic lupus erythematosus (SLE) patients, 30 stable SLE patients, and 35 healthy donors. CD4+ and CD8+ TCR α‐ and β‐chain repertoires in SLE patients showed lower diversity, reduced similarity, and more heterogeneous V–J usage, with CD8+ TCR profiles exhibiting relatively consistent stepwise changes across healthy, stable, and active groups. CD8+ T‐cell transcriptomics revealed activity‐associated upregulation of CD38 , S100A11 , IFITM3 , and LAG3 . In addition, BCR immunoglobulin heavy chain (IGH) repertoire analysis showed isotype‐specific remodeling in SLE, characterized by contracted IgM/IgD repertoires, increased IgA isotype ratio and richness, and enhanced IgG diversity. Active SLE showed further increased IgG richness with rare‐clone enrichment and higher IgM diversity. Among the TCR, BCR, and CD8+ T‐cell transcriptomic features evaluated, IGH‐derived metrics, particularly IgG‐ and IgA‐associated features, showed apparent within‐cohort discrimination between active and stable SLE. Genetic algorithm‐based label‐guided feature selection followed by hierarchical clustering revealed a multi‐omics pattern associated with disease activity within the current cohort. Our study characterized peripheral immune repertoire and transcriptional alterations in SLE and highlighted their value for characterizing disease activity.
Open AccessComprehensive Immune Repertoires of T Cell Receptor and B Cell Receptor Identify Key Immune Features Associated With Disease Activity of Systemic Lupus Erythematosus
We integrated immune repertoire sequencing (CD4+ and CD8+ T cell receptor [TCR], B cell receptor [BCR]) and transcriptional profiling to characterize the peripheral immune landscape in 32 active systemic lupus erythematosus (SLE) patients, 30 stable SLE patients, and 35 healthy donors. CD4+ and CD8+ TCR α‐ and β‐chain repertoires in SLE patients showed lower diversity, reduced similarity, and more heterogeneous V–J usage, with CD8+ TCR profiles exhibiting relatively consistent stepwise changes across healthy, stable, and active groups. CD8+ T‐cell transcriptomics revealed activity‐associated upregulation of CD38 , S100A11 , IFITM3 , and LAG3 . In addition, BCR immunoglobulin heavy chain (IGH) repertoire analysis showed isotype‐specific remodeling in SLE, characterized by contracted IgM/IgD repertoires, increased IgA isotype ratio and richness, and enhanced IgG diversity. Active SLE showed further increased IgG richness with rare‐clone enrichment and higher IgM diversity. Among the TCR, BCR, and CD8+ T‐cell transcriptomic features evaluated, IGH‐derived metrics, particularly IgG‐ and IgA‐associated features, showed apparent within‐cohort discrimination between active and stable SLE. Genetic algorithm‐based label‐guided feature selection followed by hierarchical clustering revealed a multi‐omics pattern associated with disease activity within the current cohort. Our study characterized peripheral immune repertoire and transcriptional alterations in SLE and highlighted their value for characterizing disease activity.
- 17 July 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (8)
Lung disease in adult-onset Still’s disease: a Chinese cohort study
Objectives: This study aimed to characterize the clinical phenotypes of adult-onset Still’s disease-related lung disease (AOSD-LD) in a Chinese cohort, and to evaluate the associations of lung disease and distinct radiographic patterns with macrophage activation syndrome (MAS) and disease relapse. Methods: In this cohort of 209 patients with AOSD, individuals were retrospectively stratified into AOSD-LD and non-lung disease groups based on radiographic findings. Clinical features associated with AOSD-LD were characterized. Multivariable Cox regression and subgroup analyses were performed to evaluate the impact of AOSD-LD on MAS and disease relapse. AOSD-LD was further categorized into acute exudative, interstitial and suspected pulmonary hypertension (PH) patterns to assess pattern-specific outcomes. Results: Lung involvement was identified in 49 (23.4%) patients, yet 69.4% were asymptomatic. Pleuritis emerged as the strongest independent risk factors of AOSD-LD (P < 0.0001). AOSD-LD was independently associated with both MAS (HR = 2.62, 95% CI: 1.38–4.96, P = 0.0041) and disease relapse (HR = 2.66, 95% CI: 1.50–4.71, P = 0.0012) in multivariable COX analysis. Radiographically, the acute exudative pattern was most prevalent, followed by interstitial and suspected PH patterns. Prognostic stratification revealed the acute exudative pattern was strongly associated with early MAS development (P = 0.0315), whereas the interstitial pattern was associated with a chronic, refractory course (P = 0.0059). Conclusion: AOSD-LD defines a severe disease phenotype and serves as a critical independent predictor for life-threatening MAS and chronic relapse. Differentiating radiographic patterns offers valuable prognostic insights, underscoring the necessity for chest CT screening and phenotype-guided management strategies in AOSD.
- 17 July 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (8)
Lung disease in adult-onset Still’s disease: a Chinese cohort study
Objectives: This study aimed to characterize the clinical phenotypes of adult-onset Still’s disease-related lung disease (AOSD-LD) in a Chinese cohort, and to evaluate the associations of lung disease and distinct radiographic patterns with macrophage activation syndrome (MAS) and disease relapse. Methods: In this cohort of 209 patients with AOSD, individuals were retrospectively stratified into AOSD-LD and non-lung disease groups based on radiographic findings. Clinical features associated with AOSD-LD were characterized. Multivariable Cox regression and subgroup analyses were performed to evaluate the impact of AOSD-LD on MAS and disease relapse. AOSD-LD was further categorized into acute exudative, interstitial and suspected pulmonary hypertension (PH) patterns to assess pattern-specific outcomes. Results: Lung involvement was identified in 49 (23.4%) patients, yet 69.4% were asymptomatic. Pleuritis emerged as the strongest independent risk factors of AOSD-LD (P < 0.0001). AOSD-LD was independently associated with both MAS (HR = 2.62, 95% CI: 1.38–4.96, P = 0.0041) and disease relapse (HR = 2.66, 95% CI: 1.50–4.71, P = 0.0012) in multivariable COX analysis. Radiographically, the acute exudative pattern was most prevalent, followed by interstitial and suspected PH patterns. Prognostic stratification revealed the acute exudative pattern was strongly associated with early MAS development (P = 0.0315), whereas the interstitial pattern was associated with a chronic, refractory course (P = 0.0059). Conclusion: AOSD-LD defines a severe disease phenotype and serves as a critical independent predictor for life-threatening MAS and chronic relapse. Differentiating radiographic patterns offers valuable prognostic insights, underscoring the necessity for chest CT screening and phenotype-guided management strategies in AOSD.
- Open Access
- 5 June 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (6) , 1927-1939
Identification of a metabolic–immune crosstalk in Still’s disease: monocyte/macrophage-derived immunometabolite itaconate dictates hepatic immunopathology via the CXCL10–CD8 T cell axis
Still’s disease (SD) is a chronic and systemic autoinflammatory disorder, with the possibility of resulting in life-threatening complications, including macrophage activation syndrome (MAS). The metabolic–immune interplay underlying the immunopathology of SD/MAS remains largely unexplored. In this study, we identified itaconate — a myeloid cell-specific metabolite derived from the tricarboxylic acid cycle via the enzyme ACOD1 — as a dual regulator of inflammation and chemokine-driven tissue injury in SD/MAS. Clinical metabolomics revealed elevated serum itaconate in patients with SD, attributable to peripheral blood monocytes and correlated with disease severity. This was consolidated by the identification of the Acod1 –itaconate axis in monocytes and macrophages in both a mouse model of MAS and in vitro cell cultures. Although itaconate suppressed IL-1β, IL-6, CXCL1 and CCL2 in vitro, it paradoxically amplified CXCL10 secretion in vitro and in vivo. This was in line with the observations of elevated plasma CXCL10 levels in patients with MAS. In the CpG ODN 1826-induced MAS mouse model, ablation of Acod1 ameliorated disease manifestations and hepatic inflammation, accompanied by a reduced CXCL10 level as well as attenuated hepatic infiltration of CD8 + T cells. Collectively, our study reveals a previously unrecognized metabolic–immune crosstalk in AOSD/MAS, positioning monocyte/macrophage-derived itaconate as a dual regulator that suppresses canonical pro-inflammatory cytokines while licensing CXCL10-mediated CD8 + T cell-driven tissue injury. Therefore, discovery from this study calls for scrutiny of an itaconate-based anti-inflammatory strategy in chronic inflammatory diseases.
- 5 June 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (6) , 1927-1939
Open AccessIdentification of a metabolic–immune crosstalk in Still’s disease: monocyte/macrophage-derived immunometabolite itaconate dictates hepatic immunopathology via the CXCL10–CD8 T cell axis
Still’s disease (SD) is a chronic and systemic autoinflammatory disorder, with the possibility of resulting in life-threatening complications, including macrophage activation syndrome (MAS). The metabolic–immune interplay underlying the immunopathology of SD/MAS remains largely unexplored. In this study, we identified itaconate — a myeloid cell-specific metabolite derived from the tricarboxylic acid cycle via the enzyme ACOD1 — as a dual regulator of inflammation and chemokine-driven tissue injury in SD/MAS. Clinical metabolomics revealed elevated serum itaconate in patients with SD, attributable to peripheral blood monocytes and correlated with disease severity. This was consolidated by the identification of the Acod1 –itaconate axis in monocytes and macrophages in both a mouse model of MAS and in vitro cell cultures. Although itaconate suppressed IL-1β, IL-6, CXCL1 and CCL2 in vitro, it paradoxically amplified CXCL10 secretion in vitro and in vivo. This was in line with the observations of elevated plasma CXCL10 levels in patients with MAS. In the CpG ODN 1826-induced MAS mouse model, ablation of Acod1 ameliorated disease manifestations and hepatic inflammation, accompanied by a reduced CXCL10 level as well as attenuated hepatic infiltration of CD8 + T cells. Collectively, our study reveals a previously unrecognized metabolic–immune crosstalk in AOSD/MAS, positioning monocyte/macrophage-derived itaconate as a dual regulator that suppresses canonical pro-inflammatory cytokines while licensing CXCL10-mediated CD8 + T cell-driven tissue injury. Therefore, discovery from this study calls for scrutiny of an itaconate-based anti-inflammatory strategy in chronic inflammatory diseases.
- 3 June 2026
- Published by SAGE Publications in Lupus
- Vol. 35 (11) , 1103-1119
Single-cell sequencing in systemic lupus erythematosus
Background: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by heterogeneous clinical manifestations and multi-organ involvement. Current understanding of SLE pathogenesis remains limited, particularly due to the cellular and molecular diversity of immune cells across tissues. Therefore, a comprehensive review synthesizing recent advances in applying single-cell technologies to SLE research is urgently needed to bridge this knowledge gap. Technology: Single-cell RNA sequencing (scRNA-seq) provides high-resolution transcriptomic profiling at the single-cell level. This technology facilitates the identification of rare cell subsets, the characterization of cellular states, and the elucidation of disease-specific gene expression patterns. This technology has been applied to various SLE sample types, including peripheral blood, kidney, skin, and bone marrow. Results: ScRNA-seq has revealed distinct immune cell subpopulations and their functional alterations in SLE, including aberrant B- and T-cell subsets, dysregulated interferon-stimulated genes, and pathogenic low-density granulocytes. Crucially, by deconvoluting this cellular heterogeneity, these high-resolution insights bridge the gap between fundamental pathogenesis and clinical application, uncovering cell-specific pathways that can be harnessed as actionable therapeutic targets and prognostic biomarkers. Integration with spatial transcriptomics and machine learning further enhances research capabilities. These tools allow for mapping disease-specific immune niches and predicting clinical outcomes. Ultimately, these findings underscore the transformative potential of scRNA-seq in decoding SLE pathogenesis and guiding future targeted therapies.
- 3 June 2026
- Published by SAGE Publications in Lupus
- Vol. 35 (11) , 1103-1119
Single-cell sequencing in systemic lupus erythematosus
Background: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by heterogeneous clinical manifestations and multi-organ involvement. Current understanding of SLE pathogenesis remains limited, particularly due to the cellular and molecular diversity of immune cells across tissues. Therefore, a comprehensive review synthesizing recent advances in applying single-cell technologies to SLE research is urgently needed to bridge this knowledge gap. Technology: Single-cell RNA sequencing (scRNA-seq) provides high-resolution transcriptomic profiling at the single-cell level. This technology facilitates the identification of rare cell subsets, the characterization of cellular states, and the elucidation of disease-specific gene expression patterns. This technology has been applied to various SLE sample types, including peripheral blood, kidney, skin, and bone marrow. Results: ScRNA-seq has revealed distinct immune cell subpopulations and their functional alterations in SLE, including aberrant B- and T-cell subsets, dysregulated interferon-stimulated genes, and pathogenic low-density granulocytes. Crucially, by deconvoluting this cellular heterogeneity, these high-resolution insights bridge the gap between fundamental pathogenesis and clinical application, uncovering cell-specific pathways that can be harnessed as actionable therapeutic targets and prognostic biomarkers. Integration with spatial transcriptomics and machine learning further enhances research capabilities. These tools allow for mapping disease-specific immune niches and predicting clinical outcomes. Ultimately, these findings underscore the transformative potential of scRNA-seq in decoding SLE pathogenesis and guiding future targeted therapies.
- Open Access
- 3 May 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (10) , 2149-2159
A Rare RIPK3 Variant Enhances Necroptosis and Promotes Inflammation in a Still Disease–Like Autoinflammatory Syndrome
Objective: Still disease represents a prototypical polygenic systemic autoinflammatory disease, characterized by recurrent systemic inflammation and dysregulation of innate immunity. Despite extensive clinical characterization, familial clustering Still disease remains unreported. This study investigates a novel variant underlying a distinct Still disease–like autoinflammatory syndrome. Methods: Whole‐exome sequencing was performed in a three‐generation family with three affected individuals. Functional analyses were conducted to assess the impact of the receptor‐interacting protein kinase 3 ( RIPK3 ) p.Q134K variant on kinase activity, necroptosis, and inflammatory signaling. Transcriptomic profiling of peripheral blood mononuclear cells (PBMCs) and in vitro cytokine assays were used to characterize inflammatory responses. Results: A heterozygous RIPK3 p.Q134K variant was identified in all affected individuals. Functional analyses demonstrated that this variant exhibits gain‐of‐function activity, characterized by enhanced RIPK3 kinase activity and increased RIPK3 self‐association, which in turn promote mixed‐lineage kinase domain‐like protein phosphorylation and necroptosis. RNA sequencing of PBMCs from one patient revealed marked up‐regulation of NF‐κB and MAPK signaling pathways and elevated expression of interleukin‐6, and tumor necrosis factor‐α, which was effectively suppressed by pharmacologic inhibition of RIPK3. Conclusion: This study describes a familial Still disease–like autoinflammatory syndrome caused by a gain‐of‐function RIPK3 variant. Our findings establish aberrant RIPK3 activation as a driver of autoinflammation and expand the spectrum of human RIPK3‐associated diseases.
- 3 May 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (10) , 2149-2159
Open AccessA Rare RIPK3 Variant Enhances Necroptosis and Promotes Inflammation in a Still Disease–Like Autoinflammatory Syndrome
Objective: Still disease represents a prototypical polygenic systemic autoinflammatory disease, characterized by recurrent systemic inflammation and dysregulation of innate immunity. Despite extensive clinical characterization, familial clustering Still disease remains unreported. This study investigates a novel variant underlying a distinct Still disease–like autoinflammatory syndrome. Methods: Whole‐exome sequencing was performed in a three‐generation family with three affected individuals. Functional analyses were conducted to assess the impact of the receptor‐interacting protein kinase 3 ( RIPK3 ) p.Q134K variant on kinase activity, necroptosis, and inflammatory signaling. Transcriptomic profiling of peripheral blood mononuclear cells (PBMCs) and in vitro cytokine assays were used to characterize inflammatory responses. Results: A heterozygous RIPK3 p.Q134K variant was identified in all affected individuals. Functional analyses demonstrated that this variant exhibits gain‐of‐function activity, characterized by enhanced RIPK3 kinase activity and increased RIPK3 self‐association, which in turn promote mixed‐lineage kinase domain‐like protein phosphorylation and necroptosis. RNA sequencing of PBMCs from one patient revealed marked up‐regulation of NF‐κB and MAPK signaling pathways and elevated expression of interleukin‐6, and tumor necrosis factor‐α, which was effectively suppressed by pharmacologic inhibition of RIPK3. Conclusion: This study describes a familial Still disease–like autoinflammatory syndrome caused by a gain‐of‐function RIPK3 variant. Our findings establish aberrant RIPK3 activation as a driver of autoinflammation and expand the spectrum of human RIPK3‐associated diseases.
- 26 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Benefits of adjunct plasma exchange in idiopathic inflammatory myopathy with anti-signal recognition particle antibodies: a real-world study
Objectives: The objective of this study was to compare the efficacy of adjunct plasma exchange (PE) therapy with standard therapy in idiopathic inflammatory myopathy (IIM) with anti-signal recognition particle (SRP) antibodies Methods: Anti-SRP–positive myositis patients were consecutively enrolled and followed up. Two-way ANOVA was performed to compare the pre- and post-treatment changes in myositis disease activities between the two groups. The Kaplan–Meier method was used to compare the composite end point of all-cause death and relapse after propensity score matching (PSM) and inverse probability weighting (IPW) analyses. Cox regression analyses were performed to screen long-term prognostic factors. Results: In total, 53 patients were included (35 received standard therapy, 18 received adjunct PE therapy). The PE therapy group tended to have severer muscle weakness (P = 0.027), higher levels of anti-SRP antibody titres (P = 0.001), and creatine kinase (P < 0.001), as well as higher doses of CS administration (P = 0.038). At the 4-week follow-up point, both groups achieved remarkable remission, as indicated by significant improvements in the six core set measures (CSMs), and the changes in the six CMSs were more prominent in the PE therapy group (all P < 0.001). During a median follow-up of 15 months, 26 patients reached the composite end point, and the PE therapy group had significantly better prognosis after IPW analysis (P = 0.029). In the multivariate Cox regression analyses, PE therapy [hazard ratio: 0.14 (0.03–0.57), P = 0.006] and interstitial lung disease [HR: 4.82 (1.22–19.12), P = 0.025] turned out to be independent predictors for long-term prognosis. Conclusion: Adjunct PE therapy provided quick remission and sustained benefits for IIM with anti-SRP antibodies.
- 26 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Benefits of adjunct plasma exchange in idiopathic inflammatory myopathy with anti-signal recognition particle antibodies: a real-world study
Objectives: The objective of this study was to compare the efficacy of adjunct plasma exchange (PE) therapy with standard therapy in idiopathic inflammatory myopathy (IIM) with anti-signal recognition particle (SRP) antibodies Methods: Anti-SRP–positive myositis patients were consecutively enrolled and followed up. Two-way ANOVA was performed to compare the pre- and post-treatment changes in myositis disease activities between the two groups. The Kaplan–Meier method was used to compare the composite end point of all-cause death and relapse after propensity score matching (PSM) and inverse probability weighting (IPW) analyses. Cox regression analyses were performed to screen long-term prognostic factors. Results: In total, 53 patients were included (35 received standard therapy, 18 received adjunct PE therapy). The PE therapy group tended to have severer muscle weakness (P = 0.027), higher levels of anti-SRP antibody titres (P = 0.001), and creatine kinase (P < 0.001), as well as higher doses of CS administration (P = 0.038). At the 4-week follow-up point, both groups achieved remarkable remission, as indicated by significant improvements in the six core set measures (CSMs), and the changes in the six CMSs were more prominent in the PE therapy group (all P < 0.001). During a median follow-up of 15 months, 26 patients reached the composite end point, and the PE therapy group had significantly better prognosis after IPW analysis (P = 0.029). In the multivariate Cox regression analyses, PE therapy [hazard ratio: 0.14 (0.03–0.57), P = 0.006] and interstitial lung disease [HR: 4.82 (1.22–19.12), P = 0.025] turned out to be independent predictors for long-term prognosis. Conclusion: Adjunct PE therapy provided quick remission and sustained benefits for IIM with anti-SRP antibodies.
- Open Access
- 1 September 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (2) , e001665
Glycosylation of anti-dsDNA IgG correlates with organ involvement in treatment-naïve patients with systemic lupus erythematosus
Objective: This study aimed to leverage machine learning algorithms to explore the relationship between anti-double-stranded DNA (anti-dsDNA) immunoglobulin G (IgG) glycosylation and the degree of organ involvement in patients with SLE. Methods and analysis: We enrolled 86 consecutive treatment-naïve patients with SLE positive for anti-dsDNA antibodies from the Department of Rheumatology and Immunology at Ruijin Hospital, Shanghai, between 2017 and 2019. We quantified and classified the degree of organ involvement in patients with SLE and analysed each glycoform and a combination of glycoforms of purified anti-dsDNA IgG. A random forest classifier and artificial neural network were applied to evaluate the correlation between the levels of glycoform pairs and the degree of organ involvement. Results: Pearson’s correlation analysis revealed a strong connection between the involved and uninvolved organs in patients with SLE. Random forest analysis showed that the combination of IgG1Gal and IgG3/4Bis had the highest accuracy (0.7692) and area under the curve (0.8187). In terms of predicting the degree of involvement using an artificial neural network, IgG3/4Bis and IgG1Gal showed the lowest mean squared error (0.0244). Conclusions: Our study showed the effectiveness of combining glycoforms to classify and predict the degree of SLE organ involvement. Different glycoforms were correlated with the involvement degree to various extents, and the combination of anti-dsDNA IgG3/4Bis and IgG1Gal exhibited the best correlation with organ involvement.
- 1 September 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (2) , e001665
Open AccessGlycosylation of anti-dsDNA IgG correlates with organ involvement in treatment-naïve patients with systemic lupus erythematosus
Objective: This study aimed to leverage machine learning algorithms to explore the relationship between anti-double-stranded DNA (anti-dsDNA) immunoglobulin G (IgG) glycosylation and the degree of organ involvement in patients with SLE. Methods and analysis: We enrolled 86 consecutive treatment-naïve patients with SLE positive for anti-dsDNA antibodies from the Department of Rheumatology and Immunology at Ruijin Hospital, Shanghai, between 2017 and 2019. We quantified and classified the degree of organ involvement in patients with SLE and analysed each glycoform and a combination of glycoforms of purified anti-dsDNA IgG. A random forest classifier and artificial neural network were applied to evaluate the correlation between the levels of glycoform pairs and the degree of organ involvement. Results: Pearson’s correlation analysis revealed a strong connection between the involved and uninvolved organs in patients with SLE. Random forest analysis showed that the combination of IgG1Gal and IgG3/4Bis had the highest accuracy (0.7692) and area under the curve (0.8187). In terms of predicting the degree of involvement using an artificial neural network, IgG3/4Bis and IgG1Gal showed the lowest mean squared error (0.0244). Conclusions: Our study showed the effectiveness of combining glycoforms to classify and predict the degree of SLE organ involvement. Different glycoforms were correlated with the involvement degree to various extents, and the combination of anti-dsDNA IgG3/4Bis and IgG1Gal exhibited the best correlation with organ involvement.
- Open Access
- 25 November 2024
- Published by IntechOpen
Pregnancy: A Comprehensive Review
Health during pregnancy is a key determinant of population health, with approximately 85% of women worldwide experiencing pregnancy in their lifetime. However, due to different living conditions (local policies, living habits, etc.), medical conditions (genetic testing, medication, etc.), and previous pregnancy experiences (number of previous miscarriages, etc.), pregnant women suffer from a wide range of complications at the time of conception, which will increase the likelihood of adverse pregnancy outcomes, such as miscarriages, stillbirth, preterm labor, and birth defects. These factors also contribute to the physical health of the fetus after birth. In addition, there are some areas where proper contraceptive knowledge has not been disseminated to women of childbearing age, which has led to a number of unwanted pregnancies. Doctors and the government should pay more attention to pregnant women with illnesses and provide them with appropriate support to have a smooth pregnancy and delivery.
- 25 November 2024
- Published by IntechOpen
Open AccessPregnancy: A Comprehensive Review
Health during pregnancy is a key determinant of population health, with approximately 85% of women worldwide experiencing pregnancy in their lifetime. However, due to different living conditions (local policies, living habits, etc.), medical conditions (genetic testing, medication, etc.), and previous pregnancy experiences (number of previous miscarriages, etc.), pregnant women suffer from a wide range of complications at the time of conception, which will increase the likelihood of adverse pregnancy outcomes, such as miscarriages, stillbirth, preterm labor, and birth defects. These factors also contribute to the physical health of the fetus after birth. In addition, there are some areas where proper contraceptive knowledge has not been disseminated to women of childbearing age, which has led to a number of unwanted pregnancies. Doctors and the government should pay more attention to pregnant women with illnesses and provide them with appropriate support to have a smooth pregnancy and delivery.
- 13 October 2024
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Post-COVID-19 psychological condition in systemic lupus erythematosus patients: a prospective observational study
Full Papers; Authors: J. Wu, L. Zhang, Z. Zhou, Y. Wu, Y. Sun, F. Wang, J. Teng, H. Liu, X. Cheng, Y. Su, H. Shi, Q. Hu, J. Meng, H. Chi, J. Jia, T. Liu, M. Wang, J. Li, H. Zhong, C. Yang, J. Ye
- 13 October 2024
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Post-COVID-19 psychological condition in systemic lupus erythematosus patients: a prospective observational study
Full Papers; Authors: J. Wu, L. Zhang, Z. Zhou, Y. Wu, Y. Sun, F. Wang, J. Teng, H. Liu, X. Cheng, Y. Su, H. Shi, Q. Hu, J. Meng, H. Chi, J. Jia, T. Liu, M. Wang, J. Li, H. Zhong, C. Yang, J. Ye
- Open Access
- 3 September 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (9) , e2432131
Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus
Importance: Anti–double-stranded DNA (dsDNA) antibody has been reported to have a close relationship with systemic lupus erythematosus (SLE) flares and participates in the pathogenesis of lupus nephritis (LN) as well as causing damage to other organs. However, whether early use of mycophenolate mofetil (MMF) could prevent SLE flares is not clear.Objective: To assess the efficacy and safety of MMF plus prednisone and hydroxychloroquine sulfate compared with prednisone and hydroxychloroquine sulfate alone in patients with SLE.Design, Setting, and Participants: This investigator-initiated, multicenter, observer-blinded randomized clinical trial enrolled 130 participants aged 18 to 65 years and was conducted in 3 hospitals across China. Treatment-naive patients with newly diagnosed SLE, a high titer of anti-dsDNA antibody, and no major organ involvement were included. The study was started September 1, 2018, and the follow-up was completed September 30, 2021. Data were analyzed from December 1, 2021, to March 31, 2022.Interventions: Patients were randomized 1:1 to receive oral prednisone (0.5 mg/kg/d) and hydroxychloroquine sulfate (5 mg/kg/d) (control group) or prednisone (0.5 mg/kg/d) and hydroxychloroquine sulfate (5 mg/kg/d) plus MMF (500 mg twice daily) (MMF group) for 96 weeks.Main Outcomes and Measures: The primary outcome was the proportion of patients presenting with flares according to the Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Flare Index. The secondary outcomes included the proportion with lupus low disease activity state at week 96, 36-Item Short Form Health Survey scores before and after treatment, proportion of adverse events (AEs), and changes in SLEDAI-2000 scores and prednisone doses.Results: Among 130 randomized patients (mean [SD] age, 34.5 [12.5] years; 112 [86.2%] women), 119 (91.5%) completed the follow-up. The risk of severe flare was significantly lower in the MMF group (7 of 65 [10.8%]) vs the control group (18 of 65 [27.7%]) (relative risk [RR], 0.39 [95% CI, 0.17-0.87]; P = .01). Additionally, 1 of 65 patients in the MMF group (1.5%) and 9 of 65 in the control group (13.8%) manifested LN (RR, 0.11 [95% CI, 0.01-0.85]; P = .008). Most common serious study drug–related AEs were infections (20 of 65 [30.8%] in the control group and 22 of 65 [33.8%] in the MMF group).Conclusions and Relevance: The findings of this randomized clinical trial suggest that MMF may reduce the rate of severe flare and lower the incidence of LN in patients with new-onset SLE and a high titer of anti-dsDNA antibody without major organ involvement.Trial Registration: Chinese Clinical Trial Registry: ChiCTR1800017540
- 3 September 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (9) , e2432131
Open AccessMycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus
Importance: Anti–double-stranded DNA (dsDNA) antibody has been reported to have a close relationship with systemic lupus erythematosus (SLE) flares and participates in the pathogenesis of lupus nephritis (LN) as well as causing damage to other organs. However, whether early use of mycophenolate mofetil (MMF) could prevent SLE flares is not clear.Objective: To assess the efficacy and safety of MMF plus prednisone and hydroxychloroquine sulfate compared with prednisone and hydroxychloroquine sulfate alone in patients with SLE.Design, Setting, and Participants: This investigator-initiated, multicenter, observer-blinded randomized clinical trial enrolled 130 participants aged 18 to 65 years and was conducted in 3 hospitals across China. Treatment-naive patients with newly diagnosed SLE, a high titer of anti-dsDNA antibody, and no major organ involvement were included. The study was started September 1, 2018, and the follow-up was completed September 30, 2021. Data were analyzed from December 1, 2021, to March 31, 2022.Interventions: Patients were randomized 1:1 to receive oral prednisone (0.5 mg/kg/d) and hydroxychloroquine sulfate (5 mg/kg/d) (control group) or prednisone (0.5 mg/kg/d) and hydroxychloroquine sulfate (5 mg/kg/d) plus MMF (500 mg twice daily) (MMF group) for 96 weeks.Main Outcomes and Measures: The primary outcome was the proportion of patients presenting with flares according to the Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Flare Index. The secondary outcomes included the proportion with lupus low disease activity state at week 96, 36-Item Short Form Health Survey scores before and after treatment, proportion of adverse events (AEs), and changes in SLEDAI-2000 scores and prednisone doses.Results: Among 130 randomized patients (mean [SD] age, 34.5 [12.5] years; 112 [86.2%] women), 119 (91.5%) completed the follow-up. The risk of severe flare was significantly lower in the MMF group (7 of 65 [10.8%]) vs the control group (18 of 65 [27.7%]) (relative risk [RR], 0.39 [95% CI, 0.17-0.87]; P = .01). Additionally, 1 of 65 patients in the MMF group (1.5%) and 9 of 65 in the control group (13.8%) manifested LN (RR, 0.11 [95% CI, 0.01-0.85]; P = .008). Most common serious study drug–related AEs were infections (20 of 65 [30.8%] in the control group and 22 of 65 [33.8%] in the MMF group).Conclusions and Relevance: The findings of this randomized clinical trial suggest that MMF may reduce the rate of severe flare and lower the incidence of LN in patients with new-onset SLE and a high titer of anti-dsDNA antibody without major organ involvement.Trial Registration: Chinese Clinical Trial Registry: ChiCTR1800017540